Corrigendum: Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study (Ophthalmology (2017) 124(12) (1778–1787) (S0161642017307017) (10.1016/j.ophtha.2017.06.027));Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study

Ophthalmology

Volumn 124, Issue 12, 2017, Pages 1778-1787

  Tadayoni, Ramin ^a   Waldstein, Sebastian M ^b   Boscia, Francesco ^c   Gerding, Heinrich ^d,e   Gekkieva, Margarita ^f   Barnes, Elizabeth ^f   Das Gupta, Ayan ^g   Wenzel, Andreas ^f   Pearce, Ian ^h  

^a HÔPITAL LARIBOISIÈRE   (France)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF SASSARI   (Italy)

^d Eye Clinic Pallas   (Switzerland)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f NOVARTIS PHARMA AG   (Switzerland)

^g NOVARTIS HEALTHCARE PVT LTD   (India)

^h ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ACUTE RESPIRATORY FAILURE; ADULT; AGED; ARTHRALGIA; BACKACHE; BEST CORRECTED VISUAL ACUITY; BLEPHARITIS; BRANCH RETINAL VEIN OCCLUSION; CATARACT; CENTRAL SUBFIELD THICKNESS; CONFERENCE PAPER; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE DURATION; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRY EYE; EYE IRRITATION; EYE PAIN; FALLING; FEMALE; HEAD INJURY; HEADACHE; HEART ARREST; HUMAN; HYPEREMIA; HYPERTENSION; INFLUENZA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LIMB PAIN; LOW LEVEL LASER THERAPY; LUNG TUMOR; MACULAR EDEMA; MACULAR FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RETINA HEMORRHAGE; RETINA ISCHEMIA; RETINA MACULOPATHY; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VISUAL ACUITY; VISUAL IMPAIRMENT; VISUAL SYSTEM PARAMETERS; VITREOUS BODY DETACHMENT; VITREOUS FLOATERS; VITREOUS HEMORRHAGE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; LASER COAGULATION; MULTIMODALITY CANCER THERAPY; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY; RETINA VEIN OCCLUSION; TREATMENT OUTCOME;

AGED; ANGIOGENESIS INHIBITORS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANIBIZUMAB; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85028037713     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2017.12.012     Document Type: Erratum

References (16)

1. Rogers, S., McIntosh, R.L., Cheung, N., et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117 (2010), 313–319.e1.
2. Pulido, J.S., Flaxel, C.J., Adelman, R.A., et al. Retinal Vein Occlusions Preferred Practice Pattern® Guidelines. Ophthalmology 123 (2016), P182–P208.
3. Brown, D.M., Campochiaro, P.A., Bhisitkul, R.B., et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118 (2011), 1594–1602.
4. Campochiaro, P.A., Brown, D.M., Awh, C.C., et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118 (2011), 2041–2049.
5. Lucentis® summary of product characteristics 2016. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdf. (Accessed 8 August 2016)
6. Clinicaltrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT01599650. (Accessed 8 August 2016)
7. Tadayoni, R., Waldstein, S.M., Boscia, F., et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology 123 (2016), 1332–1344.
8. Larsen, M., Waldstein, S.M., Boscia, F., et al. Individualized ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL study. Ophthalmology 123 (2016), 1101–1111.
9. Gerding, H., Mones, J., Tadayoni, R., et al. Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel. Br J Ophthalmol 99 (2015), 297–304.
10. Heier, J.S., Campochiaro, P.A., Yau, L., et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119 (2012), 802–809.
11. Campochiaro, P.A., Wykoff, C.C., Singer, M., et al. Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology 121 (2014), 2432–2442.
12. Campochiaro, P.A., Sophie, R., Pearlman, J., et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121 (2014), 209–219.
13. Shilling, J.S., Jones, C.A., Retinal branch vein occlusion: a study of argon laser photocoagulation in the treatment of macular oedema. Br J Ophthalmol 68 (1984), 196–198.
14. Pielen, A., Mirshahi, A., Feltgen, N., et al. Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmol 93 (2015), e29–e37.
15. Rezar, S., Eibenberger, K., Bühl, W., et al. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years. Acta Ophthalmol 93 (2015), 719–725.
16. Kim, S.J., Yoon, Y.H., Kim, H.K., et al. Baseline predictors of visual acuity and retinal thickness in patients with retinal vein occlusion. J Korean Med Sci 30 (2015), 475–482.